Giuseppe Sanguineti

List of Publications by Year
in descending order

47 papers	1,695 citations	331259 21 h-index	276539 41 g-index
47 all docs	47 docs citations	47 times ranked	2244 citing authors

#	Article	IF	Citations
1	A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology, 2022, 35, 21-26.	0.9	1
2	Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy. Tumori, 2021, 107, 55-63.	0.6	8
3	Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 159, 103242.	2.0	7
4	Stereotactic body radiotherapy for T1 glottic cancer: dosimetric data in 27 consecutive patients. Tumori, 2021, 107, 030089162110004.	0.6	1
5	Organ motion in linac-based SBRT for glottic cancer. Radiation Oncology, 2021, 16, 106.	1.2	6
6	Re: Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiother Oncol, 2021. 157: p. 122â€“129. Radiotherapy and Oncology, 2021, 161, 251-252.	0.3	0
7	Multiparametric MRI Evaluation of Oropharyngeal Squamous Cell Carcinoma. A Mono-Institutional Study. Journal of Clinical Medicine, 2021, 10, 3865.	1.0	6
8	Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 93-100.	0.4	15
9	A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either 64CuCl2 or 64CuPSMA PET/CT. Cancers, 2021, 13, 5564.	1.7	5
10	Comparison of rigid and deformable coregistration between mpMRI and CT images in radiotherapy of prostate bed cancer recurrence. Physica Medica, 2021, 92, 32-39.	0.4	7
11	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	2.0	11
12	Moderately accelerated intensityâ€modulated radiation therapy using simultaneous integrated boost: Practical reasons or evidenceâ€based choice? A critical appraisal of literature. Head and Neck, 2020, 42, 3405-3414.	0.9	3
13	Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions. Clinical and Translational Radiation Oncology, 2020, 21, 91-97.	0.9	3
14	Intravoxel incoherent motion diffusion-weighted imaging for oropharyngeal squamous cell carcinoma: Correlation with human papillomavirus Status. European Journal of Radiology, 2019, 119, 108640.	1.2	12
15	Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer. Head and Neck, 2017, 39, 1761-1769.	0.9	29
16	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, The, 2017, 18, 1221-1237.	5.1	226
17	The prediction of the treatment response of cervical nodes using intravoxel incoherent motion diffusion-weighted imaging. European Journal of Radiology, 2017, 92, 93-102.	1.2	41
18	Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study. Journal of Experimental and Clinical Cancer Research, 2017, 36, 191.	3.5	3

#	Article	IF	Citations
19	Impact of Sequencing Radiation Therapy and Chemotherapy on Long-Term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15-Year Follow-Up. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1201-1209.	0.4	7
20	Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 304-312.	0.4	16
21	How Much of the Future Can Be Read Through the Skin?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1355-1356.	0.4	1
22	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.. Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	2.0	112
23	Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution. Radiation Oncology, 2015, 10, 19.	1.2	23
24	HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. Acta OncolÃ³gica, 2014, 53, 662-668.	0.8	27
25	Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiation Oncology, 2014, 9, 264.	1.2	84
26	Predictors of PEG dependence after IMRTÂ±chemotherapy for oropharyngeal cancer. Radiotherapy and Oncology, 2013, 107, 300-304.	0.3	40
27	Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 235-242.	0.4	72
28	Volumetric change of human papillomavirusâ€"related neck lymph nodes before, during, and shortly after intensityâ€modulated radiation therapy. Head and Neck, 2012, 34, 1640-1647.	0.9	17
29	The Effect of a Multidisciplinary Head and Neck Cancer Clinic on Compliance with Speech Pathology Treatment. Laryngoscope, 2011, 121, S158-S158.	1.1	0
30	Weekly Doseâ€"Volume Parameters of Mucosa and Constrictor Muscles Predict the Use of Percutaneous Endoscopic Gastrostomy During Exclusive Intensity-Modulated Radiotherapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 52-59.	0.4	61
31	Level V involvement in patients with early Tâ€stage, nodeâ€positive oropharyngeal carcinoma. Laryngoscope, 2009, 119, 2165-2169.	1.1	9
32	Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2009, 185, 390-396.	1.0	20
33	Defining the Risk of Involvement for Each Neck Nodal Level in Patients With Early T-Stage Node-Positive Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1356-1364.	0.4	61
34	NTCP Modeling of Subacute/Late Laryngeal Edema Scored by Fiberoptic Examination. International Journal of Radiation Oncology Biology Physics, 2009, 75, 915-923.	0.4	42
35	Doseâ€"volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology, 2009, 93, 153-167.	0.3	249
36	Patterns of Locoregional Failure After Exclusive IMRT for Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, 737-746.	0.4	67

#	Article	IF	Citations
37	Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiotherapy and Oncology, 2008, 88, 95-101.	0.3	55
38	Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta OncolÃ³gica, 2008, 47, 301-310.	0.8	37
39	Dosimetric Predictors of Laryngeal Edema. International Journal of Radiation Oncology Biology Physics, 2007, 68, 741-749.	0.4	102
40	Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?. International Journal of Radiation Oncology Biology Physics, 2006, 64, 151-160.	0.4	41
41	Is there a â€œmucosa-sparingâ€•benefit of IMRT for head-and-neck cancer?. International Journal of Radiation Oncology Biology Physics, 2006, 66, 931-938.	0.4	63
42	Does Treatment of the Pelvic Nodes with IMRT Increase Late Rectal Toxicity over Conformal Prostate-Only Radiotherapy to 76 Gy?. Strahlentherapie Und Onkologie, 2006, 182, 543-549.	1.0	51
43	Hyperfractionated Radiotherapy for T2N0 Glottic Carcinoma: A Retrospective Analysis at 10 Years Follow-up in a Series of 60 Consecutive Patients. Tumori, 2004, 90, 317-323.	0.6	4
44	Anatomic Variations Due to Radical Prostatectomy. Strahlentherapie Und Onkologie, 2004, 180, 563-572.	1.0	26
45	Are neck nodal volumes drawn on CT slices covered by standard three-field technique?. International Journal of Radiation Oncology Biology Physics, 2004, 59, 725-742.	0.4	21
46	Radiotherapy after Prostatectomy. Tumori, 2002, 88, 445-452.	0.6	2
47	Radiotherapy after prostatectomy. Tumori, 2002, 88, 445-52.	0.6	1